RVMD Revolution Medicines

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.

Details of the abstracts are listed below:

Revolution Medicines Oral Presentations:

Title:
Presenter:Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number:CT019
Session:New Frontiers in Precision Oncology
Date/Time:April 27; 5:00 p.m. – 5:15 p.m. CST



Title:
Presenter:Anne Edwards, Ph.D.
Abstract Number:ND06
Session:New Drugs on the Horizon: Part 2
Date/Time:April 27; 3:25 p.m. – 3:40 p.m. CST
 

Revolution Medicines Poster Presentations:

Title:
Presenter:Jia Luo, M.D., Dana-Farber Cancer Institute
Abstract Number:LB218
Session:Late-Breaking Research: Clinical Research 1
Date/Time:April 28; 2:00 p.m. – 5:00 p.m. CST



Title:
Presenter:Mallika Singh, Ph.D.
Abstract Number:LB281
Session:Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time:April 29; 9:00 a.m. – 12:00 p.m. CST



Title:
Presenter:Mariela Moreno Ayala, Ph.D.
Abstract Number:6046
Session:Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity
Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST
  

Collaborator Presentations

Title:
Presenter:Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number:LB293
Session:Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time:April 29; 9:00 a.m. – 12:00 p.m. CST



Title:
Presenter:Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center
Abstract Number:5512
Session:Drug Resistance in Molecular Targeted Therapies 3
Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST



Title:
Presenter:Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number:5336
Session:CDK Inhibitors
Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST



Title:
Presenter:Jingjing Jiang, Ph.D.
Abstract Number:5691
Session:Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2
Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST



Title:
Presenter:Joshua H. Choe, Dana-Farber Cancer Institute
Abstract Number:5507
Session:Drug Resistance in Molecular Targeted Therapies 3
Date/Time:April 29; 2:00 p.m. – 5:00 p.m. CST



Title:
Presenter:Margo I. Orlen, Penn Medicine
Abstract Number:6405
Session:Checkpoints and Modulators of Tumor Microenvironment
Date/Time:April 29; 3:25 p.m. – 3:40 p.m. CST
  

About Revolution Medicines, Inc.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit  and follow us on .

Revolution Medicines Media & Investor Contact:





EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Revolution Medicines

 PRESS RELEASE

Revolution Medicines to Deliver Multiple Presentations at the 2025 Ame...

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study...

 PRESS RELEASE

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Participate in April 2025 Investor Conferences REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company’s participation are as follows: Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. E...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch